DDInter605 DDInter105
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Drotrecogin alfa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Drotrecogin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Tirofiban
Drotrecogin alfa {u} may lead to a major life threatening interaction when taken with {v} Alteplase
Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tirofiban
Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase